AllianceBernstein’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-64,310
| Closed | -$102K | – | 3353 |
|
|
2024
Q1 | $102K | Hold |
64,310
| – | – | ﹤0.01% | 3027 |
|
|
2023
Q4 | $55.2K | Sell |
64,310
-4,300
| -6% | -$3.78K | ﹤0.01% | 3123 |
|
|
2023
Q3 | $73.4K | Sell |
68,610
-4,680
| -6% | -$9.69K | ﹤0.01% | 3103 |
|
|
2023
Q2 | $190K | Buy |
73,290
+10,490
| +17% | +$37.4K | ﹤0.01% | 2994 |
|
|
2023
Q1 | $256K | Buy |
62,800
+3,300
| +6% | +$15.3K | ﹤0.01% | 2831 |
|
|
2022
Q4 | $299K | Buy |
59,500
+20,900
| +54% | +$131K | ﹤0.01% | 2875 |
|
|
2022
Q3 | $505K | Hold |
38,600
| – | – | ﹤0.01% | 2643 |
|
|
2022
Q2 | $495K | Buy |
38,600
+10,900
| +39% | +$151K | ﹤0.01% | 2688 |
|
|
2022
Q1 | $422K | Sell |
27,700
-1,900
| -6% | -$29.6K | ﹤0.01% | 2747 |
|
|
2021
Q4 | $524K | Sell |
29,600
-41,976
| -59% | -$805K | ﹤0.01% | 2721 |
|
|
2021
Q3 | $1.5M | Buy |
71,576
+35,276
| +97% | +$777K | ﹤0.01% | 2316 |
|
|
2021
Q2 | $716K | Buy |
36,300
+11,600
| +47% | +$272K | ﹤0.01% | 2664 |
|
|
2021
Q1 | $718K | Sell |
24,700
-5,100
| -17% | -$143K | ﹤0.01% | 2532 |
|
|
2020
Q4 | $903K | Sell |
29,800
-1,400
| -4% | -$30.6K | ﹤0.01% | 2338 |
|
|
2020
Q3 | $496K | Sell |
31,200
-1,300
| -4% | -$23.7K | ﹤0.01% | 2536 |
|
|
2020
Q2 | $642K | Buy |
32,500
+5,800
| +22% | +$111K | ﹤0.01% | 2449 |
|
|
2020
Q1 | $329K | Buy |
26,700
+12,000
| +82% | +$196K | ﹤0.01% | 2575 |
|
|
2019
Q4 | $272K | Buy |
14,700
+1,600
| +12% | +$23.4K | ﹤0.01% | 2813 |
|
|
2019
Q3 | $181K | Buy |
+13,100
| New | +$197K | ﹤0.01% | 2970 |
|
AllianceBernstein's NGM Position: Q2 2024 in Review
AllianceBernstein sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 64,310 shares — an estimated $102K sold.
AllianceBernstein first reported a position in NGM in Q3 2019 and held it in 19 quarters. The position peaked at $1.5M in Q3 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- AllianceBernstein reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- AllianceBernstein sold 64,310 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $102K.
- AllianceBernstein first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 19 quarters.
- AllianceBernstein's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.5M in Q3 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on AllianceBernstein's 13F filing for Q2 2024, filed 14 Aug 2024.